AI assistant
CSL Ltd. — Interim / Quarterly Report 2016
Feb 1, 2017
17854_rns_2017-02-01_fcbb6d9e-2646-44c2-b93a-bf8f4efadaf7.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
2 February 2017
==> picture [205 x 32] intentionally omitted <==
==> picture [58 x 30] intentionally omitted <==
==> picture [262 x 27] intentionally omitted <==
Changes to format of CSL Group Financial Statements
CSL Limited (ASX:CSL; USOTC:CSLLY) today released details of changes in the format of elements of the CSL Group Financial Statements. The disclosures will be applicable from the half year financial statements to be released on 15 February 2017 and will be used in the full year financial statements for the 2016/17 year and subsequent financial statements.
To assist users of the company’s financial statements, in the attachment we have presented historical data in the new format for the half year ended 31 December 2015 and the full year ended 30 June 2016.
These changes are part of the ongoing process of improving the relevance of the financial statements to users.
Changes to the Consolidated Statement of Comprehensive Income
In order to present clearer information about the operating revenues earned by the Group disclosure on the face of the Statement has been expanded to include sale of goods, pandemic facility reservation fees, royalty and licence revenue and other revenue.
Cost of sales will now include any costs directly incurred in the earning of revenue and gross profit will be calculated as Total Operating Revenue less cost of sales.
The one item previously disclosed in Other Revenue that is not included in Total Operating Revenue is Finance Revenue, this is now presented below the Operating Profit sub-total.
Operating Profit disclosed on the face of the Statement is equal to Earnings before Interest and Tax (EBIT).
==> picture [99 x 7] intentionally omitted <==
2 February 2017
==> picture [58 x 30] intentionally omitted <==
==> picture [262 x 27] intentionally omitted <==
Page 2
Changes to the Segment Note
During the first half of the financial year the Group conducted a review of internal reporting to the CEO (who is the Chief Operating Decision Maker) and determined that the separate reporting of the CSL Intellectual Property financial results was no longer relevant to the CEO review of financial performance. Additionally the separate disclosure of Unallocated Revenue less Unallocated Expense was also deemed to be unnecessary.
As a consequence the number of operating segments has been reduced to two – CSL Behring and Seqirus. The revenues and expenses of the CSL Intellectual Property segment and those previously disclosed as Unallocated are now included in the CSL Behring segment. This reflects the manner in which these costs are managed by the leadership team and reported to the CEO.
Attached is the Profit & Loss Statement (which forms a part of the Consolidated Statement of Comprehensive Income) showing the revised and prior format for each of the half year to December 2015 and the full year to June 2016, and the revised Segment disclosures for the same periods. The attachment provides a reconciliation of the Segment EBIT between the revised and prior disclosures.
For further information, please contact:
Investors: Mark Dehring Head of Investor Relations CSL Limited Telephone: +613 9389 3407 Email: [email protected]
==> picture [99 x 7] intentionally omitted <==
Attachment
Revised Disclosures
Profit & Loss Statement
| Profit & Loss Statement | 6 months to Dec-15 | ||
| New | Previous | ||
| US$m | US$m | ||
| Sales of Goods | 1/2 | 3,030.4 | 3,056.3 |
| Pandemic Facility Reservation Fees | 32.6 | ||
| Royalties and Licence Revenue | 65.6 | ||
| Other Income | 7.1 | ||
| Total Operating Revenue | 3,135.7 | ||
| Cost of Sales | (1,629.7) | (1,620.2) | |
| Gross Profit | 1,506.0 | 1,436.1 | |
| Other Revenue | 2 | 86.0 | |
| Research & Development Expenses | (283.9) | (283.9) | |
| Selling and Marketing Expenses | (281.0) | (281.0) | |
| General and Administration Expenses | 3 | (195.5) | (205.0) |
| Operating Profit | 745.6 | 752.2 | |
| Finance Costs | (33.6) | (33.6) | |
| Finance Income | 4 | 6.6 | |
| Gain on Acquisition | 176.1 | 176.1 | |
| Profit before Income Tax Expense | 894.7 | 894.7 | |
| Income Tax Expense | (175.9) | (175.9) | |
| Net Profit for the Period | 718.8 | 718.8 | |
| Profit & Loss Statement | 12 months to Jun-16 | ||
| New | Previous | ||
| US$m | US$m | ||
| Sales of Goods | 5,909.5 | 5,909.5 | |
| Pandemic Facility Reservation Fees | 68.7 | ||
| Royalties and Licence Revenue | 122.7 | ||
| Other Income | 14.4 | ||
| Total Operating Revenue | 6,115.3 | ||
| Cost of Sales | (3,052.8) | (3,034.8) | |
| Gross Profit | 3,062.5 | 2,874.7 | |
| Other Revenue | 2 | 219.7 | |
| Research & Development Expenses | (613.8) | (613.8) | |
| Selling and Marketing Expenses | (620.9) | (620.9) | |
| General and Administration Expenses | 3 | (390.3) | (408.3) |
| Operating Profit | 1,437.5 | 1,451.4 | |
| Finance Costs | (71.6) | (71.6) | |
| Finance Income | 4 | 13.9 | |
| Gain on Acquisition | 176.1 | 176.1 | |
| Profit before Income Tax Expense | 1,555.9 | 1,555.9 | |
| Income Tax Expense | (313.5) | (313.5) | |
| Net Profit for the Period | 1,242.4 | 1,242.4 |
1 Certain Pandemic Facility Reservation Fees in the NIV business were disclosed as Sales in the December 2015
accounts.These have been reclassified in the new disclosures to facilitate comparability between periods.
2 Other Revenue was detailed in a note to the accounts and included Finance Income which is now presented separately. Other Revenue in the December 2015 accounts included $6.7m that has been
reclassified as Pandemic Facility Reservation Fees.
3 Royalty expense incurred in connection with the Royalty Income has been reallocated from General and Administration Expenses to Cost of Sales.
4 Finance Income was previously disclosed in Other Revenue.
Revised Disclosures
Segment Note
| gment Note | -15 | -15 | ||||
|---|---|---|---|---|---|---|
| New DisclosureCSL BehringSeqirusTotal CSLUS$mUS$mUS$mSales of Goods2,537.4493.03,030.4Pandemic Facility Reservation Fees0.032.632.6Royalties and Licence Revenue65.60.065.6Other Income1.06.17.1Total Operating Revenue2,604.0531.73,135.7Segment Gross Profit51,383.4159.61,543.0Segment EBIT5843.0(28.4)814.6Gain on Acquistion176.1Acquisition related costs(69.0)Finance Income6.6Finance Costs(33.6)Consolidated profit before tax894.7Income Tax Expense(175.9)Consolidated Net Profit after Tax718.8Segment EBIT reconciliationSegment EBIT per December 2015 accounts841.9(97.4)744.5Transfer of CSL IP Segment EBIT23.50.0Transfer of unallocated revenue less costs(22.4)0.0Reallocation of Acquisition related costs0.069.0Revised Segment EBIT843.0(28.4)814.6Operating Profit per the Profit & Loss745.6Difference669.06 months to Dec-15 | 6 months to De | -15 | ||||
| ew DisclosureCSL | BehringSeqirusS$ US$ | Total CSLUS$ | ||||
| mm | m | |||||
| les of Goodsndemic Facility Reservation Fees | 2,537.4493.00.032.6 | 3,030.4 32.6 |
Segment Note
| Segment Note | ||||
|---|---|---|---|---|
| 12 months to | Jun-16 | |||
| New Disclosure | CSL Behring | Seqirus | Total CSL | |
| US$m | US$m | US$m | ||
| Sales of Goods | 5,257.4 | 652.1 | 5,909.5 | |
| Pandemic Facility Reservation Fees | 0.0 | 68.7 | 68.7 | |
| Royalties and Licence Revenue | 122.6 | 0.1 | 122.7 | |
| Other Income | 3.9 | 10.5 | 14.4 | |
| Total Operating Revenue | 5,383.9 | 731.4 | 6,115.3 | |
| Segment Gross Profit | 5 | 2,934.5 | 163.5 | 3,098.0 |
| Segment EBIT | 5 | 1,773.0 | (244.5) | 1,528.5 |
| Gain on Acquistion | 176.1 | |||
| Acquisition related costs | (90.9) | |||
| Finance Income | 13.9 | |||
| Finance Costs | (71.6) | |||
| Consolidated profit before tax | 1,556.0 | |||
| Income Tax Expense | (313.5) | |||
| Consolidated Net Profit after Tax | 1,242.5 | |||
| Segment EBIT reconciliation | ||||
| Segment EBIT per June 2016 accounts | 1,802.6 | (335.7) | 1,466.9 | |
| Transfer of CSL IP Segment EBIT | 27.9 | 0.0 | ||
| Transfer of unallocated revenue less costs | (57.3) | 0.0 | ||
| Reallocation of Acquisition related costs | 0.0 | 90.9 | ||
| Minor reallocations/rounding | (0.2) | 0.2 | ||
| Revised Segment EBIT | 1,773.0 | (244.6) | 1,528.4 | |
| Operating Profit per the Profit & Loss | 1,437.5 | |||
| Difference | 6 | 90.9 |
5 COGS is $37m lower and Segment EBIT $37m higher that in the Profit & Loss Statement as a result of reclassifying a fair value adjustment (required by accounting standards) to inventory as a one-off acquisition cost. This has been done to facilitate comparability between periods.
6 The difference between Segment EBIT and Operating Profit of $69.0m for the half year and $90.9m for the full year is a result of presenting one-off adjustments (that are embedded in the profit and loss statement above Operating Profit) below the the Segment EBIT line. This has been done to facilitate comparability between periods